STOCK TITAN
  1. Home
  2. News
  3. TVTX

Travere Therapeutics Inc - TVTX STOCK NEWS

Welcome to our dedicated news page for Travere Therapeutics (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Travere Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Travere Therapeutics's position in the market.

News
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Rhea-AI Summary
Travere Therapeutics, Inc. has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia. Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Travere will receive an upfront payment and be eligible to receive up to $120 million in regulatory, development, and sales-based milestone payments. Results from the urine protein/creatinine ratio (UP/C) endpoint in the study are expected in the second half of 2025 to support a submission for approval to PMDA. Travere has obtained a minority equity stake in Renalys and will be eligible to receive tiered royalties on net sales of sparsentan in Japan, South Korea, Taiwan, and the specified Southeast Asian nations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
none
-
News
Travere Therapeutics Provides Corporate Update and 2024 Outlook
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced preliminary net product sales of $15 million for FILSPARI in the fourth quarter of 2023, with total net product sales of $40 million. The company also expects to submit an sNDA to the FDA for FILSPARI in Q1 2024 and anticipates a CHMP opinion on potential approval of sparsentan in Europe. Additionally, a pivotal Phase 3 study of pegtibatinase in classical homocystinuria (HCU) is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.66%
Tags
none
-
News
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Eric Dube, Ph.D., president and CEO, will speak at 3:45 p.m. PT. The webcast will be available on Travere's Investor page at ir.travere.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
conferences
News
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
Rhea-AI Summary
Travere Therapeutics, Inc. (Nasdaq: TVTX) has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). The study aims to determine the safety and efficacy of pegtibatinase in reducing plasma total homocysteine (tHcy) levels, with topline data expected in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
clinical trial
-
News
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
Rhea-AI Summary
Travere Therapeutics, Inc. (Nasdaq: TVTX) plans to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval. The company is also implementing strategic reorganization to focus resources on ongoing FILSPARI launch in IgAN and advancement of pegtibatinase in classical HCU, extending expected cash runway into 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
none
-
News
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) to present at 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences
News
Travere Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) reported $8 million in net product sales for FILSPARI® (sparsentan) in the third quarter of 2023. The company received 430 new patient start forms and completed the sale of its bile acid product portfolio for up to $445 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.84%
Tags
earnings
-
News
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
Rhea-AI Summary
Travere Therapeutics announced positive results from two Phase 3 studies of sparsentan in treating IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). The studies showed that sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator. Sparsentan demonstrated consistent treatment effects, higher rates of remission, and lower rates of end-stage kidney disease. The drug was well-tolerated with a safety profile comparable to the active comparator.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
clinical trial
-
News
Travere Therapeutics to Report Third Quarter 2023 Financial Results
Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) will report Q3 2023 financial results on November 7, 2023, and host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
conferences earnings
News
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
Rhea-AI Summary
Travere Therapeutics to present 11 abstracts at ASN Kidney Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock TVTX logo
Travere Therapeutics Inc

Nasdaq:TVTX

TVTX Rankings

#3122 Ranked by Market Cap
#5106 Ranked by Stock Gains
N/A Ranked by Dividends

TVTX Stock Data

484.81M
60.60M
0.65%
115.18%
13.93%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego